Global Calcitonin Gene Related Peptide Type 1 Receptor Market By Type (AFAP-3 , AGN-241689 , CGRP , Erenumab , and Others), By Application (Cardiovascular , Metabolic Disorders , Dental Pain , and Others), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

Published date: Jul 2022
Report ID: 53376
Number of Pages: 307
Format:

- 1. Calcitonin Gene Related Peptide Type 1 Receptor Market Introduction
  - 1.1. Definition
  - 1.2. Taxonomy
  - 1.3. Research Scope
- 2. Executive Summary
  - 2.1. Key Findings by Major Segments
  - 2.2. Top strategies by Major Players
- 3. Global Calcitonin Gene Related Peptide Type 1 Receptor Market Overview
  - 3.1. Calcitonin Gene Related Peptide Type 1 Receptor Market Dynamics
    3.1.1. Drivers
    3.1.2. Opportunities
    3.1.3. Restraints
    3.1.4. Challenges
  - 3.2. PESTLE Analysis
  - 3.3. Opportunity Map Analysis
  - 3.4. PORTER'S Five Forces Analysis
  - 3.5. Market Competition Scenario Analysis
  - 3.6. Product Life Cycle Analysis
  - 3.7. Opportunity Orbits
  - 3.8. Production Analysis by Region/Company
  - 3.9. Industry chain Analysis
  - 3.10. Marketing Strategy
- 4. Global Calcitonin Gene Related Peptide Type 1 Receptor Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
  - 4.1. Global Calcitonin Gene Related Peptide Type 1 Receptor Market Analysis by Type: Introduction
  - 4.2. Market Size and Forecast by Region
  - 4.3. AFAP-3
  - 4.4. AGN-241689
  - 4.5. CGRP
  - 4.6. Erenumab
  - 4.7. Others
- 5. Global Calcitonin Gene Related Peptide Type 1 Receptor Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
  - 5.1. Global Calcitonin Gene Related Peptide Type 1 Receptor Market Analysis by Application: Introduction
  - 5.2. Market Size and Forecast by Region
  - 5.3. Cardiovascular
  - 5.4. Metabolic Disorders
  - 5.5. Dental Pain
  - 5.6. Others
- 6. Global Calcitonin Gene Related Peptide Type 1 Receptor Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
  - 6.1. North America
    6.1.1. North America Calcitonin Gene Related Peptide Type 1 Receptor Market: Regional Trend Analysis
    6.1.1.1. US
    6.1.1.2. Canada
    6.1.1.3. Mexico
  - 6.2.1. Europe
    6.2.1. Europe Calcitonin Gene Related Peptide Type 1 Receptor Market: Regional Trend Analysis
    6.2.1.1. Germany
    6.2.1.2. France
    6.2.1.3. UK
    6.2.1.4. Russia
    6.2.1.5. Italy
    6.2.1.6. Spain
    6.2.1.7. Rest of Europe
  - 6.3. Asia-Pacific
    6.3.1. Asia-Pacific Calcitonin Gene Related Peptide Type 1 Receptor Market: Regional Trend Analysis
    6.3.1.1. China
    6.3.1.2. Japan
    6.3.1.3. Korea
    6.3.1.4. India
    6.3.1.5. Rest of Asia-Pacific
  - 6.4. Latin America
    6.4.1. Latin America Calcitonin Gene Related Peptide Type 1 Receptor Market: Regional Trend Analysis
    6.4.1.1. Brazil
    6.4.1.2. Argentina
    6.4.1.3. Rest of Latin America
  - 6.5. Middle East and Africa
    6.5.1. Middle East and Africa Calcitonin Gene Related Peptide Type 1 Receptor Market: Regional Trend Analysis
    6.5.1.1. GCC
    6.5.1.2. South Africa
    6.5.1.3. Israel
    6.5.1.4. Rest of MEA
- 7. Global Calcitonin Gene Related Peptide Type 1 Receptor Market Competitive Landscape, Market Share Analysis, and Company Profiles
  - 7.1. Market Share Analysis
  - 7.2. Company Profiles
  - 7.3. Allergan Plc
    7.3.1. Company Overview
    7.3.2. Financial Highlights
    7.3.3. Product Portfolio
    7.3.4. SWOT Analysis
    7.3.5. Key Strategies and Developments
  - 7.4. Amgen Inc
    7.4.1. Company Overview
    7.4.2. Financial Highlights
    7.4.3. Product Portfolio
    7.4.4. SWOT Analysis
    7.4.5. Key Strategies and Developments
  - 7.5. Biohaven Pharmaceutical Holding Company Ltd
    7.5.1. Company Overview
    7.5.2. Financial Highlights
    7.5.3. Product Portfolio
    7.5.4. SWOT Analysis
    7.5.5. Key Strategies and Developments
  - 7.6. Eli Lilly and Company
    7.6.1. Company Overview
    7.6.2. Financial Highlights
    7.6.3. Product Portfolio
    7.6.4. SWOT Analysis
    7.6.5. Key Strategies and Developments
  - 7.7. Fortress Biotech Inc
    7.7.1. Company Overview
    7.7.2. Financial Highlights
    7.7.3. Product Portfolio
    7.7.4. SWOT Analysis
    7.7.5. Key Strategies and Developments
  - 7.8. Merck & Co Inc
    7.8.1. Company Overview
    7.8.2. Financial Highlights
    7.8.3. Product Portfolio
    7.8.4. SWOT Analysis
    7.8.5. Key Strategies and Developments
  - 7.9. Teva Pharmaceutical Industries Ltd
    7.9.1. Company Overview
    7.9.2. Financial Highlights
    7.9.3. Product Portfolio
    7.9.4. SWOT Analysis
    7.9.5. Key Strategies and Developments
  - 7.10. Vertex Pharmaceuticals Inc
    7.10.1. Company Overview
    7.10.2. Financial Highlights
    7.10.3. Product Portfolio
    7.10.4. SWOT Analysis
    7.10.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- Allergan Plc
- Amgen Inc
- Biohaven Pharmaceutical Holding Company Ltd
- Eli Lilly and Company
- Fortress Biotech Inc
- Merck & Co Inc
- Teva Pharmaceutical Industries Ltd. Company Profile
- Vertex Pharmaceuticals Inc
Settings

Related Reports

Our Clients

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $5,999 $2,999 USD / per unit save 50%	Multi User $7,999 $3,499 USD / per unit save 55%	Corporate User $12,999 $4,499 USD / per unit save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 2,999)	Buy Now ($ 3,499)	Buy Now ($ 4,499)